Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| LL22NC03-N14H11.1 regulates the m6A modification of MYC and promotes glycolytic activity in hepatocellular carcinoma cells by inhibiting IGF2BP3 ubiquitination degradation. | J Exp Clin Cancer Res | 2025 | 41331843 | PubTator, text mining | PubMed |
| Hsa_circ_0003611 hinders the transformation of mesenchymal stem cells into osteosarcoma cells through suppressing MYC by IGF2BP3 via m6A modification. | Biol Res | 2025 | 41318550 | PubTator, text mining | PubMed |
| M6A modification mediates CACNA1A stability to drive the progression of ovarian cancer by inhibiting ferroptosis. | J Ovarian Res | 2025 | 41316396 | PubTator, text mining | PubMed |
| Positive feedback loop of IGF2BP3/IL6ST/STAT3 facilitates malignant progression in colorectal cancer. | J Transl Med | 2025 | 41286950 | PubTator, text mining | PubMed |
| Extracellular vesicle-mediated transfer of MIR22HG inhibits the colonization of enteric neural crest cells in the colon by decreasing MPP3 expression. | Commun Biol | 2025 | 41286351 | PubTator, text mining | PubMed |
| IGF2BP3 regulates EMP1 stability in an m6A-dependent manner and activates the TGF-β pathway to promote pancreatic cancer invasion. | Cell Death Dis | 2025 | 41285728 | PubTator, text mining | PubMed |
| RMND5A upregulation via IGF2BP3-mediated m6A RNA modification enhances malignant traits and immune evasion in laryngeal squamous cell carcinoma cells. | Hum Cell | 2025 | 41284154 | PubTator, text mining | PubMed |
| IGF2BP3 remodels the microRNA targeting landscape in MLL-AF4 leukemia. | bioRxiv | 2025 | 41279410 | PubTator, text mining | PubMed |
| Immune transcriptomic differences in paediatric patients with SARS-CoV-2 compared to other lower respiratory tract infections. | bioRxiv | 2025 | 41279033 | PubTator, text mining | PubMed |
| Hepatitis B virus X protein promotes the progression and immune escape of hepatocellular carcinoma by activating KLF16-C12orf49-PD-L1 axis. | Oncogene | 2025 | 41238928 | PubTator, text mining | PubMed |
| METTL14 promotes ferroptosis during the development of cisplatin-induced kidney injury by stabilizing ERFE through IGF2BP3-dependent m6A methylation. | J Trace Elem Med Biol | 2025 | 41205320 | PubTator, text mining | PubMed |
| IGF2BP3 promotes acute myeloid leukemia cell progression by regulating Semaphorin 4D stability in an m6A-dependent manner. | Leuk Res | 2025 | 41187599 | PubTator, text mining | PubMed |
| Prognostic role and mutational characteristics of N6-methyladenosine-related genes in lung adenocarcinoma. | Oncol Lett | 2025 | 41158316 | PubTator, text mining | PubMed |
| Identification of a novel m6A RNA methylation regulator-based signature for prognosis and immune landscape prediction in hepatocellular carcinoma. | Sci Rep | 2025 | 41120498 | PubTator, text mining | PubMed |
| Long non-coding RNA FEZF1-AS1 suppresses ferroptosis in multiple myeloma cells through KIAA1429-mediated m6A modification. | Hum Cell | 2025 | 41085851 | PubTator, text mining | PubMed |
| Deciphering the crucial role of IGF2BP3 in modulating stemness traits of salivary adenoid cystic carcinoma. | Med Oncol | 2025 | 41082045 | PubTator, text mining | PubMed |
| Interaction between IGF2BP3 and RP11-480I12.5 facilitates proliferation and suppresses apoptosis in non-small cell lung cancer. | Eur J Med Res | 2025 | 41063234 | PubTator, text mining | PubMed |
| The IGF2BP3-FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer. | Cell Death Dis | 2025 | 41053003 | PubTator, text mining | PubMed |
| Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization. | Mol Cancer | 2025 | 41039575 | PubTator, text mining | PubMed |
| PARK7-driven IGF2BP3-K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma. | Redox Biol | 2025 | 41038069 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=9